Health care provider and patient views on prescribing opioids for cancer survivors
Summary
Researchers at the University of Calgary want to know what doctors and patients think about the prescription of narcotic/opioid medications (like morphine, oxycodone and fentanyl) to cancer survivors. We want to know what health care providers think about when they prescribe opioids to cancer patients. Likewise, we want to hear what patient’s think about being prescribed opioids.
We will be completing interviews with participants to talk about their views on opioid prescriptions. Interviews will take place via telephone or electronic platform (i.e., Zoom). Participants will be provided with a $25.00 gift card for reimbursement of their time.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Accepts healthy participants: Yes
Inclusion criteria:
Who is eligible:
1) Health care providers (oncology physicians, primary care physicians, palliative care physicians and nurse practitioners) in Alberta who prescribe opioids to cancer patients
2) Patients aged 18 and older who have early stage (I-III) head and neck, breast, lung, colorectal, or prostate cancer who are taking opioids or have taken opioids for longer than 3 months in the past 12 month period
3) Must be able to read and speak English
4) Must be willing to participate in a one on one interview for approximately 60 minutes
5) Must be able to engage with interview team via telephone or electronic platform
Exclusion criteria:
Who is NOT eligible:
1) Participants under the age of 18
2) Participants who are not able to read and speak English
3) Patient with life expectancy <6 months, being treated for terminal illness, will be excluded from this study
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Colleen Cuthbert
Principal investigator:
Colleen Cuthbert
REB-ID:
HREBA.CC-20-0500